Ocugen Inc
NASDAQ:OCGN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.3581
1.98
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OCGN stock under the Base Case scenario is 0.62 USD. Compared to the current market price of 1.12 USD, Ocugen Inc is Overvalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Ocugen Inc
Run backtest to discover the historical profit from buying and selling OCGN based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Ocugen Inc
Balance Sheet Decomposition
Ocugen Inc
Current Assets | 18.6m |
Cash & Short-Term Investments | 15.7m |
Other Current Assets | 2.9m |
Non-Current Assets | 21.9m |
PP&E | 17.5m |
Other Non-Current Assets | 4.5m |
Current Liabilities | 18m |
Accounts Payable | 3.4m |
Accrued Liabilities | 4.5m |
Other Current Liabilities | 10.1m |
Non-Current Liabilities | 5.6m |
Long-Term Debt | 1.6m |
Other Non-Current Liabilities | 4.1m |
Earnings Waterfall
Ocugen Inc
Revenue
|
8.2m
USD
|
Operating Expenses
|
-59.9m
USD
|
Operating Income
|
-51.7m
USD
|
Other Expenses
|
5.8m
USD
|
Net Income
|
-45.9m
USD
|
Free Cash Flow Analysis
Ocugen Inc
USD | |
Free Cash Flow | USD |
OCGN Profitability Score
Profitability Due Diligence
Ocugen Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Ocugen Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
OCGN Solvency Score
Solvency Due Diligence
Ocugen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Ocugen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OCGN Price Targets Summary
Ocugen Inc
According to Wall Street analysts, the average 1-year price target for OCGN is 7.14 USD with a low forecast of 6.06 USD and a high forecast of 8.4 USD.
Shareholder Yield
Current shareholder yield for OCGN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
OCGN Price
Ocugen Inc
Average Annual Return | 96.49% |
Standard Deviation of Annual Returns | 278.25% |
Max Drawdown | -99% |
Market Capitalization | 288.3m USD |
Shares Outstanding | 257 354 000 |
Percentage of Shares Shorted | 24.37% |
Ownership
OCGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.
Contact
IPO
Employees
Officers
The intrinsic value of one OCGN stock under the Base Case scenario is 0.62 USD.
Compared to the current market price of 1.12 USD, Ocugen Inc is Overvalued by 44%.